News & Press Releases

Enamine, the leading provider of chemical compounds and drug discovery services, and Pohang Accelerator Laboratory (PAL), a science and technology institution in South Korea, have signed a Memorandum of Understanding (MOU) to advance collaborative drug discovery efforts. The memorandum outlines a joint commitment to pursue research and development in fragment-based drug discovery and hit optimization. Both parties aim to provide a streamlined path from fragment identification to advanced leads by combining advanced screening technologies with fast-track chemical development.

Korean Chemical Society (KCS), an academic organization that promotes research and education in the field of chemistry and the chemistry profession, and Enamine, the leading provider of chemical compounds and drug discovery services, have signed a Memorandum of Understanding (MOU) to collaborate in the field of chemical science. The document outlines a shared framework for cooperation across academic and business domains. The aim of the MOU is to strengthen research and scientific exchange between the two organizations to drive progress in chemical science.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against the hundred most difficult to address biological areas and clinically relevant key drug targets.

Enamine, the leading provider of chemical compounds and drug discovery services, and ChemPass, a contract research organization for computational and AI-assisted software, today announced their start of strategic partnership to provide hit discovery solutions to their customers.

Enamine, Chemspace, and PharmAI Discovery GmbH (PAID) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy. This collaboration brings together the success of Enamine’s discovery biology and chemistry competencies, Chemspace’s expertise in ultra-large chemical space exploration for drug discovery, and PAID’s AI-powered molecular discovery platform to identify and develop promising drug candidates faster and with greater precision, both for conventional and molecular radiotherapy and radio diagnostics.

Elsevier, a global leader in information and analytics, and Enamine, a global leader in supplying small molecules and early drug discovery services, have announced a partnership to integrate Enamine's database of over 43 million make-on-demand (MADE) analog compounds into Reaxys. The integration will provide chemists with unparalleled access to a diverse array of chemical compounds for accelerated drug discovery and materials science research.

Enamine, a scientifically driven provider of chemistry and biology services with the world’s largest catalog of building blocks screening compounds, announced today performance results for Enamine Fast MADE building blocks.

Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are pleased to announce an expansion of their collaboration to improve delivery times of molecules from Chemspace Freedom Space.

Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are excited to announce a collaboration to unveil the real potential of Enamine’s chemistry capabilities and deliver unparalleled discovery solutions. By combining their unique strengths, both companies aim to accelerate and enhance the process of identifying and developing new active molecules.

FarmHannong, a leading company in the Korean agricultural industry, and Enamine Ltd, the world’s premier provider of chemical building blocks, screening compounds, and integrated discovery chemistry services, have announced the start of their collaboration.

Syntekabio collaborates with global compound supplier Enamine on AI-driven synthetic drug development and global market expansion through a strategic partnership.

K-MEDI hub (Daegu-Gyeongbuk Medical Innovation Foundation, Chairman Jin-Young Yang) announced on the 29th that it has signed a Memorandum of Understanding (MOU) with Enamine to develop the K-DEL platform technology and establish a collaborative research framework for drug development.

Burlingame, CA (USA), Kyiv (Ukraine) – August 16th, 2024 — Collaborative Drug Discovery (CDD), a leader in providing scientific informatics solutions, announced today that its flagship platform, CDD Vault, now includes the complete compound collection of Enamine, a leading provider of chemical compounds and early discovery services, within its AI module for structural similarity searches. This integration enhances the platform's capabilities, offering users an unprecedented breadth of chemical diversity and precision in their research endeavors.

Hamburg, Germany, and Kyiv, Ukraine — August 14th, 2024 — iniuva GmbH, a Hamburg-based pioneering biotech startup specializing in AI-powered drug discovery, and Enamine Ltd, a Kyiv-based leading provider of chemical compounds and related services, today announced a collaborative research and development program.

Cresset, an in silico solutions provider for drug discovery, has extended its collaboration with Enamine.

Cresset and the chemical and biological CRO are looking to develop targeted protein degraders (TPDs), which can be used to develop therapeutic interventions for a number of diseases.

We are pleased to announce the release of a new product from Enamine – Compound Tuning Kits that help you adjust properties of the developed molecules. Today, we introduce Basicity-Tuning Kits of amines as the most common building blocks of drugs playing a significant role in numerous biological systems.

Tokyo, Japan, and Kyiv, Ukraine, 21 June 2024. SyntheticGestalt, an AI company specializing in the life sciences domain, and Enamine, a pioneer in the creation of ultra-large chemical spaces of highly feasible compounds, announced today a new research program involving the application of AI for novel drug discovery, followed by biological tests of REAL compounds directly at Enamine (B-REAL).

We are excited to share some news about the strategic partnership between Enamine and Genez International.

We understand the challenges that scientists face while navigating through huge chemical spaces. Our task is to simplify and streamline this process.

Please welcome a new access point to Enamine REAL Space and Chemspace Freedom Space 3.0 – Hyperspace! It is a fantastic search tool created by our partners from Alipheron.